No Data
No Data
H.C. Wainwright Initiates Immix Biopharma(IMMX.US) With Buy Rating, Announces Target Price $7
H.C. Wainwright analyst Robert Burns initiates coverage on $Immix Biopharma(IMMX.US)$ with a buy rating, and sets the target price at $7.According to TipRanks data, the analyst has a success rate of 2
Immix Biopharma Initiated at Buy by HC Wainwright & Co.
Immix Biopharma Initiated at Buy by HC Wainwright & Co.
Buy Rating for Immix Biopharma Backed by Promising N-GENIUS Platform and Strong NXC-201 Sales Potential
Immix Biopharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/01/2024 278.38% HC Wainwright & Co. → $7 Initiates Coverage On → Buy 08/14/2023 656.76% Roth MKM → $14
Express News | Immix Biopharma, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $7
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today
No Data